TS Overexpression in SCLC: Mechanism and Therapeutic Targeting

Completed

Conditions studied: Small Cell Lung Cancer

In brief

The purpose of this research study is to determine the amount of a protein named thymidine synthase that is being made by cancer and to develop laboratory models called PDX (patient derived xenografts) to learn more about SCLC (small cell lung cancer) and to begin testing new treatments.

Key facts

Study ID

NCT03741829

Run by

Wake Forest University Health Sciences

People needed

12

Starts

2017-06-14

Expected to finish

2020-01-03

Last updated by the study team

2020-02-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients undergoing a diagnostic FNA by the following diagnostic modalities utilizing FNA: Endobronchial Ultrasound Guided Transbronchial Needle Aspiration (EBUS- TBNA) or conventional transbronchial FNA.
• Patients must have radiographic evidence for presumed lung cancer or have a previously diagnosed SCLC with clinical evidence of recurrence. Patients undergoing FNA of potential SCLC metastates to lymph nodes are also included (e.g., patients with abnormal mediastinal lymphadenopathy). FNA biopsies from separate locations in the same patient will be considered separate specimens.
• Age >18 years. Used to define adult age that can independently provide consent.
• Ability to understand and the willingness to sign a written informed consent document.

You may not qualify if…

• Patients whose FNA biopsy is unable to provide classification by pathology or is non-diagnostic.

Where it is running

• Wake Forest University Health Sciences — Winston-Salem, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.